SecBot SecBot
8-K ·Filed Jun 9, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001628280-26-041962
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor PALISADE-4 topline results in Q2 2026 as the key binary catalyst. The ICH E1 milestone is a necessary but not sufficient step toward an NDA, FDA alignment on safety database requirements remains unresolved. The stock's $21M market cap implies binary risk around the Phase 3 readout.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5351
T+0 close · Jun 9, 2026 · via day close
Latest settled
−53.99%
T+60 · $0.2462
Vs SPY
−60.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $0.5351entry
  2. T+1 · 5mo ago +7.10%α +5.40% · $0.5731
  3. T+5 · 5mo ago +28.95%α +25.52% · $0.6900
  4. T+20 · 4mo ago −53.43%α −57.05% · $0.2492
  5. T+60 · 2mo ago −53.99%α −60.57% · $0.2462
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, with over 1,500 subjects receiving at least one dose, over 300 with at least 6 months of exposure, and over 100 with at least 12 months. This is a regulatory milestone for the NDA pathway, but the company has not yet aligned with the FDA on specific requirements. Topline results from the pivotal PALISADE-4 Phase 3 trial are expected in Q2 2026, and from the Phase 2 repeat dose study in Q3 2026.

Key Facts

  • Fasedienol program exceeded ICH E1 minimum safety exposure recommendations as of May 31, 2026
  • Over 1,500 subjects received at least a single exposure to fasedienol
  • Over 300 subjects with at least 6 months of exposure
  • Over 100 subjects with at least 12 months of exposure
  • Vistagen has not yet aligned with the FDA on specific patient exposure requirements for an NDA
  • Topline results from PALISADE-4 Phase 3 trial expected in Q2 2026
  • Topline results from Phase 2 Repeat Dose study expected in Q3 2026
  • Fasedienol has FDA Fast Track designation for acute treatment of social anxiety disorder

Financial Impact

No financial figures disclosed; milestone is regulatory/clinical, not financial

Risk Factors

  • FDA has not yet agreed that the safety database is sufficient for NDA submission
  • PALISADE-4 may fail to replicate PALISADE-2 positive results
  • Company may need additional financing to complete development and regulatory submission

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-041962
Document: vtgnex99106092026.htm0001628280-26-041962
Document: 0001628280-26-041962-index-headers.html0001628280-26-041962
Document: 0001628280-26-041962-index.html0001628280-26-041962
Document: 0001628280-26-041962.txt0001628280-26-041962

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026